Erasca, Inc. announced its financial results for Q4 and FY 2025, highlighting encouraging early clinical activity for ERAS-0015 and a successful $259 million financing. The company expects to fund operations into H2 2028, with promising data anticipated in 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.